TAO LIU, Ph.D.
Chair of Department of Molecular & Cellular Pharmacology,
School of Pharmaceutical Sciences, Peking University
Principal Investigator at State Key Laboratory of Natural and Biomimetic Drugs
Office: +86 10 82805519
Email: taoliupku@pku.edu.cn
http://sklnbd.bjmu.edu.cn/team/liutao/LiuLab.html
Education
09/2005 – 07/2011 Ph.D., Biochemistry, The Ohio State University, Columbus, OH, USA
07/2001 – 07/2005 B.S., Biological Science, Nankai University, China
Research Experience
2016.7 - Current
Tenure Track Assistant Professor, Peking University, School of Pharmaceutical Sciences
Principal Investigator, State Key Laboratory of Natural and Biomimetic Drugs
● Development of novel biotherapeutics. We use a combination of molecular biology approaches, including genetic code expansion and molecular evolution (phage display, yeast display, library screening, etc.) to develop novel protein, antibody, and cell-based therapeutics.
● Study the function of post-translational modification (PTM). We have a broad interest in the function and regulation of protein PTMs, such as phosphorylation, acetylation and ubiquitination. We are especially interested in protein tyrosine phosphorylation and how it involves in disease conditions.
2011.7 – 2016.3
Postdoctoral Research Associate, Department of Chemistry, the Scripps Research Institute.
Advisor: Prof. Peter G. Schultz
Scientist (part time), California Institute for Biomedical Research (Calibr)
● Exploring expanded genetic codes in a variety of applications, including enhancing protein thermostabilities, probing protein post-translational modifications and modification of natural peptide products.
● Development of antibody-CDR engineering strategies for generation of long acting therapeutic proteins and peptides in variety of disease models.
2005.7 – 2011.6
Graduate Research Associate, Department of Chemistry, The Ohio State University.
Advisor: Prof. Dehua Pei
● Development of chemical methodologies for the combinatorial synthesis and screening of cyclic peptide libraries, and peptide engineering for enhanced binding affinity, solubility and cell permeability;
● Application of cyclic peptide libraries for the identification of inhibitors against protein receptors, protein domains and enzymes, as well as the hit optimization and biological evaluation.
Key Words
Chemical Biology, Synthetic Biology, Biotherapeutics, Expanded Genetic Codes, Post-Translational Modifications, Antibody Engineering, Phage Display, Genome Editing, etc.
Publications
1. Xinyu Ling, Bingteng Xie, Xiaoqin Gao, Liying Chang, Wei Zheng, Heqi Chen, Yujia Huang, Linzhi Tan, Mo Li* and Tao Liu*. “Improving the Efficiency of Precise Genome Editing with Site-Specific Cas9-Oligonucleotide Conjugates”. Science Advances. 2020; Apr 8th. aaz0051
2. Xuewen Qin, Hongting Tang, Wenbing Cao, Zhen Dai, Liming Hu, Yujia Huang, Tao Liu*. “An Orthogonal Tyrosyl-tRNA Synthetase/tRNA Pair from a Thermophilic Bacterium for an Expanded Eukaryotic Genetic Code”. Biochemistry 2020 59(1): 90-99.
3. Xinyu Ling, Heqi Chen, Wei Zheng, Liying Chang, Yong Wang, Tao Liu*. “Site-specific protein modification by genetic encoded disulfide compatible thiols” "Chin Chem Lett. 2019. 31(1): 163-166.
4. Jack C. Li, Tao Liu, Yan Wang, Angad P. Mehta, and Peter G. Schultz*. “Enhancing Protein Stability with Genetically Encoded Noncanonical Amino Acids” J Am Chem Soc. 2018, 140 (47), 15997–16000
5. Hongting Tang, Zhen Dai, Xuewen Qin, Wenkang Cai, Liming Hu, Yujia Huang, Wenbing Cao, Fan Yang, Chu Wang, and Tao Liu*. “Proteomic Identification of Protein Tyrosine Phosphatase and Substrate Interactions in Living Mammalian Cells by Genetic Encoding of Irreversible Enzyme Inhibitors.” J Am Chem Soc. 2018 140(41):13253-13259.
6. Yujia Huang, Tao Liu*. “Therapeutic applications of genetic code expansion” Synth Syst Biotechnol. 2018 3(3):150-158.
7. Tao Liu* (Lead Contact), Panpan Jia, Huailei Ma, Sean A. Reed, Xiaozhou Luo, H. Benjamin Larman, Peter G. Schultz*. “Construction and Screening of a Lentiviral Secretome Library.” Cell Chem Biol2017, 24, 767-771
This work is reported byWuXi Media and Chinese Health News (2017)
8. Xiaozhou Luo, Guangsen Fu, Rongsheng Wang, Xueyong Zhu , Claudio Zambaldo , Renhe Liu , Tao Liu , Xiaoxuan Lyu , Jintang Du , Weimin Xuan , Anzhi Yao , Sean Reed , Mingchao Kang , Yuhan Zhang , Hui Guo , Chunhui Huang , Pengyu Yang , Ian Wilson , Feng Wang and Peter G. Schultz. “Genetically encoding phosphotyrosine and its nonhydrolyzable analog in bacteria.” Nat Chem Biol 2017, Aug;13(8):845-849.
9. Yan Liu, Ying Wang, Yong Zhang, Tao Liu, Haiqun Jia, Huafei Zou, Qiangwei Fu, Yuhan Zhang, Lucy Lu, Elizabeth Chao, Holly Parker, Van Nguyen-Tran, Weijun Shen, Danling Wang, Peter G. Schultz and Feng Wang. “Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones.” ACS Chem Biol 2016, 11 (11), 2991-2995.
10. Tao Liu, Yan Wang, Xiaozhou Luo, Jack Li, Sean A. Reed, Han Xiao, Travis S. Young, and Peter G. Schultz*. “Enhancing Protein Stability with Extended Disulfide Bonds”Proc Natl Acad Sci USA2016, May 24; 113(21):5910-5.
11. Xiaozhou Luo, Claudio Zambaldo, Tao Liu, Yuhan Zhang, Weimin Xuan, Chen Wang, Sean A. Reed, Peng-YuYang, Rongsheng E. Wang, Tsotne Javahishvili, and Peter G. Schultz* and Travis S. Young*."Recombinant Thiopeptides Containing Noncanonical Amino Acids".Proc Natl Acad Sci USA 2016, Mar 29;113(13):3615-20.
12. Xiaozhou Luo#, Tao Liu#(Co-first Authorship), Ying Wang, Haiqun Jia, Yuhan Zhang, Dawna Caballero, Juanjuan Du, Rongsheng E. Wang, Danling Wang, Peter G. Schultz* and Feng Wang*. "An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold"Angewandte Chemie 2015, 54(48):14531-4.
13. Tao Liu#, Juanjuan Du#, Xiaozhou Luo, Peter G. Schultz and Feng Wang*. “Homogeneously modified immunoglobulin domains for therapeutic applications”. Curr Opin Chem Biol 2015, 28, 66-74.
14. Han Xiao, Weimin Xuan, Sida Shao, Tao Liu, Peter G. Schultz*. “Genetic Incorporation of ε-N-2-Hydroxyisobutyryl-lysine into Recombinant Histones” ACS Chem Biol 2015, 10 (7), 1599–1603.
15. Tao Liu, Guangsen Fu, Xiaozhou Luo, Yan Liu, Ying Wang, Rongsheng E. Wang, Peter G. Schultz* and Feng Wang*. "Rational Design of Antibody Protease Inhibitors" J Am Chem Soc 2015, 137, 4042.
(This work is recommended by Faculty of 1000 as “Exceptional” DOI: 10.3410/f.725390332.793505297, http://f1000.com/prime/725390332)
16. Rongsheng E. Wang#, Tao Liu#(Co-first Authorship), Ying Wang, Yu Cao, Xiaozhou Luo, Vishal Deshmukh, Chan Hyuk Kim, Brian Lawson, Stephanie Pinkerston*, Feng Wang*, Peter G Schultz*. "An Immunosuppressive Antibody-Drug Conjugate"J Am Chem Soc2015, 137, 3229
17. Tao Liu#, Yong Zhang#, Yan Liu#, Ying Wang, Haiqun Jia, Mingchao Kang, Xiaozhou Luo, Dawna Caballero, Jose Gonzalez, Danling Wang, Ashley Woods, Peter G. Schultz* and Feng Wang*. "Functional Human Antibody CDR Fusions as Long-Acting Therapeutic Endocrine Agonists" Proc Natl Acad Sci USA 2015, 112, 1356-61.
(This work is highlighted by Nature Reviews Drug Discovery 14, 166 (2015) This work is reported worldwide by major scientific media including ScienceDaily news, Drug Discovery News, GEN News, Scripps news, and radio station 24/7 News https://pnas.altmetric.com/details/3416965/news)
18. Tao Liu, Yan Liu, Ying Wang, Mitchell Hull, Peter G. Schultz* and Feng Wang*. "Rational Design of CXCR4 Specific Antibodies with Elongated CDRs"J Am Chem Soc 2014, 136, 10557.
19. Ziqing Qian, Patrick G. Dougherty, Tao Liu, Shameema Oottikkal, Patrick G. Hogan, Christopher M. Hadad, and Dehua Pei*." Structure-Based Optimization of a Peptidyl Inhibitor against Calcineurin-Nuclear Factor of Activated T Cell (NFAT) Interaction" J Med Chem 2014, 57, 7792.
20. Ziqing Qian, Tao Liu, Yu-Yu Liu, Roger Briesewitz, Amy Barrios, Sissy Jhiang, and Dehua, Pei*. "Efficient Delivery of Cyclic Peptides into Mammalian Cells with Short Sequence Motifs" ACS Chem Biol 2013, 8, 423.
21. Varun Dewan#, Tao Liu#(Co-first Authorship), Kuan-Ming Chen, Ziqing Qian, Yong Xiao, Lawrence Kleiman, Kiran V. Mahasenan, Chenglong Li, Hiroshi Matsuo, Dehua Pei*, and Karin Musier-Forsyth*. "Cyclic Peptide Inhibitors of HIV-1 Capsid-Human Lysyl-tRNA Synthetase Interaction" ACS Chem Biol 2012, 7, 761.
22. Tao Liu, Ziqing Qian, Qing Xiao and Dehua Pei*. “High-Throughput Screening of One-Bead-One-Compound Libraries: Identification of Cyclic Peptidyl Inhibitors against Calcineurin/NFAT Interaction” ACS Comb Sci 2011, 13, 537.
23. Tao Liu, Yu Liu, Hung-Ying Kao and Dehua Pei*. “Membrane permeable cyclic peptidyl inhibitors against human peptidylprolyl isomerase Pin1.”J Med Chem2010, 53, 2494.
24. Tao Liu, Sang Hoon Joo, Jeffrey L. Voorhees, Charles L. Brooks and Dehua Pei*. “Synthesis and screening of a cyclic peptide library: Discovery of small-molecule ligands against human prolactin receptor” Bioorg Med Chem 2009, 17, 1026.
25. Tao Liu, Long chen, Sen Hou, Yonglai Xue and Xizeng Feng*. “Non-viral gene delivery carrier of probe type host molecule --Interactions between DNA and β-cyclodextrin derivative complexes (I)” Chinese Science Bulletin 2006, 51, 530.
26. Yu Liu*, Guosong Chen, Yong Chen, Fei Ding, Tao Liu, and Yanli Zhao. “Molecular binding behavior of pyridine-2, 6-dicarbox-amide-bridged bis(β-cyclodextrin) with oligopeptides: switchable molecular binding mode”Bioconjug Chem 2004, 15, 300.
Patent
1. Feng Wang, Yong Zhang, Tao Liu, Juanjuan Du, Ying Wang, Yan, Liu, Peter G. Schultz. “Immunoglobulin fusion proteins and compositions thereof” PCT/US2014/046429 WO/2015/006744
2. Feng Wang, Rongsheng E. Wang, Tao Liu, Peter G. Schultz. “Antibody drug conjugates for the treatment of immune conditions” PCT/US2016/013189WO/2016/115218
